Skip to main content

Advertisement

SpringerLink
Log in

The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information

  • Comment
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

The diagnostic reach of nonalcoholic fatty liver disease (NAFLD) is broad, stretching from simple steatosis to cirrhosis. Expanded disease definitions are an important cause of waste in health care. Now is the time to revise the definition of NAFLD to include only those who have developed advanced fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Comparing NAFLD with CHD.

References

  1. Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).

    Article  Google Scholar 

  2. Estes, C. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).

    Article  CAS  Google Scholar 

  3. Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).

    Article  CAS  Google Scholar 

  4. Kim, D. et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57, 1357–1365 (2013).

    Article  CAS  Google Scholar 

  5. Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265–1273 (2017).

    Article  Google Scholar 

  6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).

    Google Scholar 

  7. Tuzcu, E. M. et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103, 2705–2710 (2001).

    Article  CAS  Google Scholar 

  8. US Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA 320, 272–280 (2018).

    Google Scholar 

  9. Rowe, I. A. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol. Hepatol. 3, 66–72 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leeds Institute for Medical Research, University of Leeds, Leeds, UK

    Ian A Rowe

  2. Leeds Liver Unit, St James’s University Hospital, Leeds, UK

    Richard Parker

Authors
  1. Ian A Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian A Rowe.

Additional information

Related links

NAFLD Simulator: www.nafldsimulator.org

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rowe, I.A., Parker, R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. Nat Rev Gastroenterol Hepatol 16, 449–450 (2019). https://doi.org/10.1038/s41575-019-0168-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-019-0168-0

  • Springer Nature Limited

Search

Navigation